Induced-fit docking studies of the active and inactive states of protein tyrosine kinases

Related Experiment Video

Updated: Jun 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Haizhen Zhong1, Ly M Tran, Jenna L Stang

  • 1Department of Chemistry, The University of Nebraska at Omaha, Omaha, NE 68182, USA. hzhong@mail.unomaha.edu

Journal of Molecular Graphics & Modelling
|September 22, 2009
PubMed

Insights

Induced-fit docking accurately predicted kinase inhibitor binding poses. Imatinib binds EGFR strongly, while nilotinib

Area of Science:

  • Oncology
  • Pharmacology
  • Structural Biology

Background:

  • Tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, imatinib, and dasatinib are crucial for treating solid tumors.
  • Understanding EGFR and ABL kinase-ligand interactions is key for designing novel TKIs.

Purpose of the Study:

  • To perform induced-fit docking (IFD) of 18 diverse kinase inhibitors against EGFR and both active/inactive states of ABL.
  • To validate the IFD protocol's accuracy in reproducing native ligand poses and binding interactions.
  • To identify key residues involved in kinase inhibitor binding for structure-based drug design.

Main Methods:

  • Induced-fit docking (IFD) simulations were conducted.
  • 18 structurally diverse kinase inhibitors were docked against EGFR and ABL (active and inactive states).
  • Docked poses and binding interactions were analyzed and compared with experimental data.

Main Results:

  • The IFD protocol successfully reproduced native ligand poses for various kinase inhibitors.
  • Docking results align with existing experimental data.
  • Imatinib showed strong binding to EGFR but weak binding to active ABL.
  • Erlotinib's sensitivity to EGFR may involve Cys797.
  • Key residues for EGFR and ABL inhibitor design were identified (e.g., EGFR: Cys797, Thr790; ABL: Thr315, Met318).
  • Minimum H-bond requirements explain nilotinib's efficacy against imatinib-resistant mutants.

Conclusions:

  • IFD is a reliable method for predicting kinase inhibitor binding modes.
  • Specific residues in EGFR and ABL are critical for TKI efficacy and resistance.
  • This study provides insights for rational design of next-generation TKIs, including those overcoming resistance.

More Related Videos

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Related Concept Videos

Induced-fit Model01:13

Induced-fit Model

Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical characteristics of...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...